Efficacy of second-generation-antipsychotics in the treatment of negative symptoms of schizophrenia: A meta-analysis of randomized clinical trials;Eficacia de los antipsicóticos de segunda generación en el tratamiento de los síntomas negativos de esquizofrenia: Un metaanálisis de ensayos clínicos aleatorizados

Revista de Psiquiatria y Salud Mental

Volumn 4, Issue 3, 2011, Pages 126-143

  Darbà, Josep ^a   Minoves, Agns ^b   Rojo, Emilio ^c   Jimenez, Francesca ^c   Rejas, Javier ^d  

^a UNIVERSITY OF BARCELONA   (Spain)

^b Health Economics and Outcomes Research   (Spain)

^c HOSPITAL GENERAL DE GRANOLLERS   (Spain)

^d PFIZER INC   (United States)

Author keywords

Efficacy; Meta analysis; Negative symptoms; Randomized clinical trials; Schizophrenia; Second generation antipsychotics

Indexed keywords

AMISULPRIDE; HALOPERIDOL; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ARTICLE; COCHRANE LIBRARY; DRUG EFFECT; DRUG EFFICACY; HUMAN; MEDLINE; META ANALYSIS; NEGATIVE SYNDROME; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCISEARCH; STATISTICAL ANALYSIS;

EID: 80053386088     PISSN: 18889891     EISSN: 19894600     Source Type: Journal    
DOI: 10.1016/j.rpsm.2011.02.005     Document Type: Article

References (41)

1. J.P. Lindenmayer, A. Khan, A. Iskander, M.T. Abad, and B. Parker A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia J Clin Psychiatry 68 2007 368 379 (Pubitemid 46506800)
2. P. Milev, B.C. Ho, S. Amdt, and N.C. Andreasen Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up Am J Psychiatry 162 2005 495 506 (Pubitemid 40343916)
3. E.S. Herbener, C. Rosen, T. Khine, and J.A. Sweeney Failure of positive but not negative emotional valence to enhance memory in schizophrenia J Abnorm Psychol 116 2007 43 55 (Pubitemid 46328614)
4. W. Carpenter Jr. Unmet therapeutic needs Schizophr Bull 31 2005 793 794
5. J. Kane Commentary: Consensus Statement on Negative Symptoms Schizophr Bull 32 2006 223 224
6. N.C. Andreasen American Psychiatric Association Scale for the assessment of positive symptoms (SAPS) and scale for the assessment of negative symptoms (SANS) 2000 Handbook of Psychiatric Measures Washington, DC
7. N. Andreasen Department of Health and Human Services, Public Health Administration Modified scale for the assessment of negative symptoms 1984 National Institutes of Mental Health publication ADM 9-102 Rockville
8. S.R. Kay, L.A. Opler, and J.-P. Lindenmayer The positive and negative syndrome scale (PANSS): rationale and standardization Br J Psychiatry 155 1989 59 65 (Pubitemid 19270851)
9. J.E. Overall, and D.R. Gorham The Brief Psychiatric Rating Scale Psychol Rep 10 1962 799 812
10. nd edn 1988 Lawrence Eribaum Associates Hillsdale, NJ p. 20-26
11. R. DerSimonian, and N. Laird Meta-analysis in clinical trials. Controlled Clin Trials 7 1986 177 188
12. W.G. Cochran The Combination of estimates from different experiments Biometrics 10 1954 101 129
13. J.P.T. Higgins, S.G. Thompson, J.J. Deeks, and D.G. Altman Measuring inconsistency in meta-analyses BMJ 327 2003 557 560 (Pubitemid 37088507)
14. C. Begg, and M. Mazumbar Operating characteristics of a rank correlation test for publication bias Biometrics 50 1994 1088 1101
15. M. Egger, G.D. Smith, M. Schneider, and C. Minder Bias in meta-analysis detected by a simple, graphical test BMJ 315 1997 629 634 (Pubitemid 27387172)
16. A. Breier, R.W. Buchanan, B. Kirkpatrick, O.R. Davis, D. Irish, and A. Summerfelt Effects of Clozapine on Positive and Negative Symptoms in Outpatients with Schizophrenia Am J Psychiatry 151 1994 20 26 (Pubitemid 24020107)
17. D.L. Zimbroff, J.M. Kane, C.A. Tamminga, D.G. Daniel, R.J. Mack, and P.J. Wozniak Controlled, Dose-Response Study of Sertindole and Haloperidol in the Treatment of Schizophrenia Am J Psychiatry 155 1997 1303 1304
18. M.H. Corrigan, C.C. Gallen, M.L. Bonura, and K.M. Merchant Effectiveness of the selective D4 antagonist sonepiprazole in schizophrenia: a placebo- controlled trial Biol Psychiatry 55 2004 445 451 (Pubitemid 38338530)
19. Y. Lecrubier, P. Quintin, M. Bouhassira, E. Perrin, and S. Lancrenon The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial Acta Psychiatr Scand 114 2006 319 327 (Pubitemid 44521299)
20. H.J. Möller, M. Riedel, N. Müller, W. Fischer, and R. Kohnen Zotepine Versus Placebo in the Treatment of Schizophrenic Patients with Stable Primary Negative Symptoms: A Randomized Double-Blind Multicenter Trial Pharmacopsychiatry 37 2004 270 278 (Pubitemid 39587054)
21. C.M. Beasley, T. Sanger, W. Satterlee, G. Tollefson, P. Tran, and S. Hamilton Olanzapine versus placebo: Results of a double-blind, fixed-dose olanzapine trial Psychopharmacology 124 1996 159 167
22. S.H Hamilton, D.A. Revicki, L.A. Genduso, and C.M. Beasley Jr. Olanzapine versus placebo and haloperidol: Quality of life and efficacy results of the North American double-blind trial Neuropsychopharmacology 18 1998 41 49 (Pubitemid 28116372)
23. J.G. Small, S.R. Hirsch, L.A. Arvanitis, B.G. Miller, and C.G. Link Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo Arch Gen Psychiatry 54 1997 549 557 (Pubitemid 27258553)
24. L.A. Arvanitis, B.G. Miller, and R.L. Borison Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo Biol Psychiatry 42 1997 233 246 (Pubitemid 27325811)
25. S.E. Purdon, A. Malla, A. Labelle, and W. Lit Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol J Psychiatry Neurosci 26 2001 137 149 (Pubitemid 32373127)
26. S.R. Marder, and C.M. Richard Risperidone in the Treatment of Schizophrenia Am J Psychiatry 151 1994 825 835
27. G. Chouinard, B. Jones, G. Remington, D. Bloom, D. Addington, and G.W. MacEwan A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients J Clin Psychopharmacol 13 1993 25 40 (Pubitemid 23030357)
28. S.R. Hirsch, W. Kissling, J. Bäuml, A. Power, and R. O'Connor A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia J Clin Psychiatry 63 2002 516 523 (Pubitemid 34680361)
29. S. Brook, J. Walden, I. Benattia, C.O. Siu, and S.J. Romano Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study Psychopharmacology 178 2005 514 523 (Pubitemid 40486992)
30. M. Petit, J. Raniwalla, J. Tweed, E. Leutenegger, S. Dollfus, and F. Kelly A Comparison of an Atypical and Typical Antipsychotics, Zotepine Versus Haloperidol in Patients With Acute Exacerbation of Schizophrenia: A Parallel-Group Double-Blind Trial Psychopharmacol Bull 32 1996 81 87
31. F. Song, T.A. Sheldon, A.J. Sutton, K.R. Abrams, and D.R. Jones Methods for exploring heterogeneity in meta-analysis Eval Salud Profess 24 2001 126 151 (Pubitemid 33089375)
32. S.L. Eckert, P.M. Diamond, A.L. Miller, D.I. Velligan, L.G. Funderburg, and J.E. True A comparison of instrument sensitivity to negative symptom change Psychiatry Res 63 1996 67 75 (Pubitemid 26228649)
33. A.J. Sutton, K.R. Abrams, and D.R. Jones An illustrated guide to the methods of meta-analysis J Eval Clin Pract 7 2001 135 148 (Pubitemid 32489007)
34. J.M. Davis, N. Chen, and I.D. Glick A meta-analysis of the efficacy of second-generation antipsychotics Arch Gen Psychiatry 60 2003 553 564 (Pubitemid 36682312)
35. M. Arato, R. O'Connor, and H.Y. Meltzer A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study Int Clin Psychopharmacol 17 2002 207 215
36. S.J. Cooper, J. Tweed, J. Raniwalla, A. Butler, and C. Welch A placebo-controlled comparison of zotepine versus chlorpromazine in patients with acute exacerbation of schizophrenia Acta Psychiatr Scand 101 2000 218 225 (Pubitemid 30108372)
37. S.J. Cooper, A. Butler, J. Tweed, C. Welch, and J. Raniwalla Zotepine in the prevention of recurrence: a randomized, double-blind, placebo-controlled study for chronic schizophrenia Psychopharmacology 150 2000 237 243 (Pubitemid 30447842)
38. D.G. Daniel, D.L. Zimbroff, S.G. Potkin, K.R. Reeves, E.P. Harrigan, and M. Lakshminarayanan Ziprasidone 80 mg/day and 160 mg/day in the Acute Exacerbation of Schizophrenia and Schizoaffective Disorder: A 6-week Placebo-Controlled Trial Neuropsychopharmacology 20 1999 491 505 (Pubitemid 29123876)
39. J.M. Danion, W. Rein, and O. Fleurot Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Amisulpride Study Group Am J Psychiatry 156 1999 610 616 (Pubitemid 29162984)
40. H. Loo, M.F. Poirier-Littre, M. Theron, W. Rein, and O. Fleurot Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia Br J Psychiatry 170 1997 18 22 (Pubitemid 27404772)
41. R.L. Borison, L.A. Arvanitis, and B.G. Miller ICI 204,636, an atypical antipsychotic: Efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia J Clin Psychopharmacol 16 1996 158 169 (Pubitemid 26141753)